ethyl (5-methoxy-2,3-dihydro-1H-inden-1-ylidene)ethanoate | 73809-30-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: ethyl (5-methoxy-2,3-dihydro-1H-inden-1-ylidene)ethanoate
• 英文别名: Ethyl 2-[(1E)-5-methoxy-2,3-dihydroinden-1-ylidene]acetate；ethyl 2-(5-methoxy-2,3-dihydroinden-1-ylidene)acetate
• CAS: 73809-30-0
• 化学式: C₁₄H₁₆O₃
• 分子量: 232.279
• InChiKey: CSYXYILSDUPUAF-UHFFFAOYSA-N

物化性质

• 熔点：
  50-51 °C
• 沸点：
  130-150 °C(Press: 0.3 Torr)
• 密度：
  1.183±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl (5-methoxy-2,3-dihydro-1H-inden-1-ylidene)ethanoate 在 palladium on activated charcoal sodium hydroxide 、 三甲基氯硅烷 、 三氯化铝 、 氢气 、 三苯基膦 、 乙硫醇 、 1,1'-azodicarbonyl-dipiperidine 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 5.0~10.0 ℃ 、275.79 kPa 条件下， 生成
  参考文献：
  名称：

  Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups—new classes of PPAR γ/δ and PPAR α/γ/δ agonists

  摘要：

  Modulation of PPAR activities represents an attractive approach for the treatment of diabetes with associated cardiovascular complications. The indanylacetic acid structural motif has proven useful in the generation of potent and tunable PPAR ligands. Modification of the substituents on the linker and the heterocycle tail group allowed for the modulation of the selectivity at the different receptor subtypes. Compound 33 was evaluated in vivo, where it displayed the desired reduction of glucose levels and increase in HDL levels in various animal models. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.11.025
• 作为产物：
  描述：

  5-甲氧基-1-茚酮 、 溴乙酸乙酯 在 锌 、 氯化亚铜 作用下， 以 四氢呋喃 为溶剂， 反应 16.25h， 生成 ethyl (5-methoxy-2,3-dihydro-1H-inden-1-ylidene)ethanoate
  参考文献：
  名称：

  Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation

  摘要：

  本发明涉及一种新型的茚基乙酸衍生物，其在糖尿病、肥胖症、高脂血症和动脉粥样硬化等疾病的治疗中具有用途。本发明还涉及制备茚基乙酸衍生物的中间体以及制备方法。

  公开号：

  US08541618B2

文献信息

• BRIDGED AND FUSED HETEROCYCLIC ANTIDIABETIC COMPOUNDS
  申请人：Josien Hubert B.

  公开号：US20110312995A1

  公开（公告）日：2011-12-22

  This invention provides for certain bridged and fused heterocyclic compounds of the formula (I) or a pharmaceutically acceptable salt, ester solvate or prodrug thereof wherein: L is: (II) and the other variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.

  这项发明提供了一些具有以下结构式（I）的桥接和融合杂环化合物或其药用可接受的盐、酯、溶剂合物或前药：其中：L为：（II），其他变量在此处定义；这些创新化合物是G蛋白偶联受体40（GPR40，也称为游离脂肪酸受体FFAR）的激动剂。该发明还涉及含有这些化合物的药物组合物，以及利用这些化合物调节哺乳动物胰岛素水平的用途。这些化合物可以用于预防和治疗2型糖尿病，以及预防和治疗与2型糖尿病相关的疾病，如胰岛素抵抗、肥胖和脂质紊乱。
• METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE
  申请人：T3D Therapeutics, Inc.

  公开号：US20180153859A1

  公开（公告）日：2018-06-07

  The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of cognitive disorders based on the ApoE4 genotype of human subjects.

  本发明提供了关于人类主体的ApoE4基因型的吲哌乙酸及其衍生物的治疗和/或预防认知障碍的方法。
• METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES
  申请人：T3D Therapeutics, Inc.

  公开号：US20180153860A1

  公开（公告）日：2018-06-07

  The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of cognitive disorders.

  本发明提供了茚乙酸及其衍生物，以及用于治疗和/或预防认知障碍的方法。
• Indane acetic acid derivatives and their use as pharmaceutical agents
  申请人：Wickens Philip

  公开号：US20050107392A1

  公开（公告）日：2005-05-19

  This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases and to pharmaceutical compositions containing these compounds.

  本发明涉及新型茚基乙酸衍生物，其在治疗糖尿病、肥胖症、高脂血症和动脉粥样硬化等疾病方面有用，并涉及含有这些化合物的制药组合物。
• Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation
  申请人：Lowe Derek B.

  公开号：US20090047687A1

  公开（公告）日：2009-02-19

  This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.

  本发明涉及一种新型的茚环乙酸衍生物，其在治疗糖尿病、肥胖症、高脂血症和动脉粥样硬化等疾病方面具有用途。本发明还涉及在制备茚环乙酸衍生物时有用的中间体和制备方法。